LINDYProven
STAT+: Pharmalittle: We’re reading about Trump tariff plans, FDA’s OK for a Lilly obesity pill, and more
Stat News|4/2/2026
P
pharmalittle
87 stories tracked
Executive summary being generated...
Lindy
0
Breaking
0
Unverified
44
Activity (Last 30 Days)
1
1
1
1
1
1
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
2026-03-052026-04-02
Top Publishers
Stat News44 stories
Stories (Latest First)
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more
Stat News|4/1/2026
LINDYsurvived 2 days
STAT+: Pharmalittle: We’re reading about pharma delaying launches in Europe, Lilly and Biogen deals, and more
Stat News|3/31/2026
LINDYsurvived 3 days
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News|3/30/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Novo Nordisk boosting consumer focus, FDA approving a gene therapy, and more
Stat News|3/27/2026
LINDYsurvived 7 days
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News|3/26/2026
LINDYsurvived 8 days
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News|3/25/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about a Trump drug pricing flaw, a Gilead deal, and more
Stat News|3/24/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Iran war’s impact on pharma supply chain, a Pfizer Lyme vaccine, and more
Stat News|3/23/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about TrumpRx expectations, a high-dose version of Wegovy, and more
Stat News|3/20/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about a Lilly weight loss trial, TrumpRx shortcomings, and more
Stat News|3/19/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about TrumpRx prices, a J&J psoriasis pill, and much more
Stat News|3/18/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Trump’s drug pricing moves, a GSK asthma drug, and more
Stat News|3/17/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about obesity pill trial results, cholesterol guidelines, and more
Stat News|3/16/2026
UNVERIFIEDSingle Source
STAT+: Up and down the ladder: The latest comings and goings
Stat News|3/13/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Trump and drug prices, biotechs pushing back, and more
Stat News|3/13/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about telehealth prescribers, a Lilly push against compounding, and more
Stat News|3/12/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about the FDA warning Novo Nordisk, Lilly investing in China, and more
Stat News|3/11/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about a U.S. senator probing FDA, BioNTech founders leaving, and much more
Stat News|3/10/2026
UNVERIFIEDSingle Source
STAT+: Pharmalot: We’re reading about a lack of FDA adcomms, FDA loosening biosimilar rules, and more
Stat News|3/9/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about an FDA-UniQure tussle, a Pfizer obesity drug approval in China, and more
Stat News|3/6/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about TrumpRx shortcomings, Lilly targeting employers, and more
Stat News|3/5/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about an FDA-UniQure feud, Pfizer’s ‘problem’ with the agency, and more
Stat News|3/3/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more
Stat News|3/2/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about FDA and a ‘smear campaign,’ Cigna buying a large pharmacy, and more
Stat News|2/27/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about a puzzling FDA rejection, a Lilly weight loss pill, and more
Stat News|2/26/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Trump’s drug-price claims, a Novo deal for obesity drugs, and more
Stat News|2/25/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about an FDA plan for ultra-rare drugs, Novo cutting GLP-1 drug prices, and more
Stat News|2/24/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more
Stat News|2/23/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more
Stat News|2/20/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about the FDA pushing OTC meds, its new trial standards, and much more
Stat News|2/19/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about an FDA reversal on a Moderna vaccine, the U.K. life sciences sector, and more
Stat News|2/18/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about China’s homegrown GLP-1 drugs, a puzzling FDA rejection, and more
Stat News|2/17/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Lilly bulking up on weight-loss drugs, scrutiny of a 340B contractor, and more
Stat News|2/13/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Sanofi replacing its CEO, MFN drug pricing opposed by conservatives, and more
Stat News|2/12/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about FDA rejecting a Moderna vaccine, compounding in the crosshairs and more
Stat News|2/11/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about FDA rejecting a rare disease drug, a warning to a Hims compounding pharmacy and more
Stat News|2/10/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Novo Nordisk suing Hims & Hers, deals by Lilly and Takeda, and more
Stat News|2/9/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about TrumpRx, Hims & Hers selling compounded Wegovy pill, and more
Stat News|2/6/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about Super Bowl drug ads, an FTC deal with Express Scripts, and more
Stat News|2/5/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about worries over FDA voucher program, a new U.S. Novo exec, and more
Stat News|2/4/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about a Pfizer obesity pill, Florida’s failed drug importation plan, and more
Stat News|2/3/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about obesity drug sales, India’s biopharma research push, and more
Stat News|2/2/2026
UNVERIFIEDSingle Source
STAT+: Pharmalittle: We’re reading about pharma lobbying, an FDA gene-editing pathway, and more
Stat News|1/26/2026